Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz gmbh - naftifino hidrochloridas - odos tirpalas - 10 mg/g; 10 mg/ml - naftifine

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

adeofarma, uab - naftifino hidrochloridas - odos tirpalas - 10 mg/ml - naftifine

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

ideal trade links, uab - naftifino hidrochloridas - kremas - 10 mg/g - naftifine

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

nenurodyta - naftidrofurilas - tabletė - 100 mg - naftidrofuryl

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivakaftoras - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ir 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - orkambi tabletės yra nurodyta gydyti cistine fibroze (cf) pacientams nuo 6 metų ir vyresni, kurie yra homozigotiniam už f508del mutacija cftr geno. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cistinė fibrozė - kiti kvėpavimo sistemos produktai - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

liphatech s.a.s, bonnel bp3, fr-47480 pont du casse (prancūzija). - difetialonas, 3-(1rs, 3rs, 1rs,3rs)-3-(4 bromobifenil-4-)-1,2,3,4 tetrahidro-1-naftil)-4-hidroksi-1-benzo-2-onas - veikliosios medžiagos cas nr.: 104653-34-1, eb nr.: -, veikliosios medžiagos pavadinimas: difetialonas, 3-(1rs, 3rs, 1rs,3rs)-3-(4 bromobifenil-4-)-1,2,3,4 tetrahidro-1-naftil)-4-hidroksi-1-benzo-2-onas, koncentracija: 0.0025% , veiklioji - rodenticidai

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

liphatech s.a.s, bonnel bp3, fr-47480 pont du casse (prancūzija). - difetialonas, 3-(1rs, 3rs, 1rs,3rs)-3-(4 bromobifenil-4-)-1,2,3,4 tetrahidro-1-naftil)-4-hidroksi-1-benzo-2-onas - veikliosios medžiagos cas nr.: 104653-34-1, eb nr.: -, veikliosios medžiagos pavadinimas: difetialonas, 3-(1rs, 3rs, 1rs,3rs)-3-(4 bromobifenil-4-)-1,2,3,4 tetrahidro-1-naftil)-4-hidroksi-1-benzo-2-onas, koncentracija: 0.0025% , veiklioji - rodenticidai